









Mercados
/
Ações
/
nasdaq-gild
/

Gilead Sciences Inc

GILD

152.540USD

+3.170+2.12%

Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min

189.45BValor de mercado

23.43P/L TTM



Gilead Sciences Inc

152.540

+3.170+2.12%

Visão Geral Serviços Financeiros Análises Empresa

Visão Geral

Serviços Financeiros

Análises

Empresa

Mais detalhes de Gilead Sciences Inc Empresa

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.

Informações de Gilead Sciences Inc



Código da empresaGILD

Nome da EmpresaGilead Sciences Inc

Data de listagemJan 22, 1992

CEOO'Day (Daniel P)

Número de funcionários17600

Tipo de títulosOrdinary Share

Fim do ano fiscalJan 22

Endereço333 Lakeside Dr

CidadeFOSTER CITY

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal94404-1147

Telefone16505743000

Sitehttps://www.gilead.com/

Código da empresaGILD

Data de listagemJan 22, 1992

CEOO'Day (Daniel P)

Executivos da empresa Gilead Sciences Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Ms. Johanna Mercier

Chief Commercial Officer

76.00K

-3000.00%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

26.06K

+1516.00%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

11.75K

+1516.00%

Ms. Kelly A. Kramer

Independent Director

1.34K

Mr. Harish Manwani

Independent Director

Mr. Andrew D. (Andy) Dickinson

Chief Financial Officer

Mr. Daniel P. O'Day

Chairman of the Board, Chief Executive Officer

Dr. Sandra J. Horning, M.D.

Independent Director

Mr. Javier J. Rodriguez

Independent Director

Dr. Jeffrey A. (Jeff) Bluestone, Ph.D.

Independent Director

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Ms. Johanna Mercier

Chief Commercial Officer

76.00K

-3000.00%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

26.06K

+1516.00%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

11.75K

+1516.00%

Ms. Kelly A. Kramer

Independent Director

1.34K

Mr. Harish Manwani

Independent Director

Mr. Andrew D. (Andy) Dickinson

Chief Financial Officer

Detalhamento da receita

Moeda: USDAtualizado em: ter, 6 de jan

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

Por EmpresaUSD

Nome

Receita

Proporção

Biktarvy

3.69B

47.46%

Descovy

698.00M

8.98%

Royalty Contract and other revenues

423.00M

5.44%

Genvoya

376.00M

4.84%

Trodelvy

357.00M

4.60%

Outro

2.23B

28.68%

Por RegiãoUSD

Nome

Receita

Proporção

United States

5.01B

64.45%

Europe

1.51B

19.47%

Other Locations

837.00M

10.77%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Biktarvy

3.69B

47.46%

Descovy

698.00M

8.98%

Royalty Contract and other revenues

423.00M

5.44%

Genvoya

376.00M

4.84%

Trodelvy

357.00M

4.60%

Outro

2.23B

28.68%

Distribuição de ações

Atualizado em: dom, 16 de nov

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

9.71%

BlackRock Institutional Trust Company, N.A.

5.86%

State Street Investment Management (US)

4.76%

Fidelity Management & Research Company LLC

4.34%

Capital World Investors

3.64%

Outro

71.69%

Investidores

Proporção

The Vanguard Group, Inc.

9.71%

BlackRock Institutional Trust Company, N.A.

5.86%

State Street Investment Management (US)

4.76%

Fidelity Management & Research Company LLC

4.34%

Capital World Investors

3.64%

Outro

71.69%

Tipos de investidores

Investidores

Proporção

Investment Advisor

54.77%

Investment Advisor/Hedge Fund

25.91%

Pension Fund

2.80%

Research Firm

2.77%

Hedge Fund

2.00%

Bank and Trust

1.86%

Sovereign Wealth Fund

1.73%

Insurance Company

0.15%

Venture Capital

0.10%

Outro

7.91%

Participação acionária institucional



Atualizado em: qui, 1 de jan

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q4

3520

1.15B

92.30%

-4.70M

2025Q3

3433

1.13B

91.16%

+23.58K

2025Q2

3388

1.12B

90.01%

-12.02M

2025Q1

3442

1.12B

90.14%

-10.49M

2024Q4

3313

1.12B

90.13%

+4.63M

2024Q3

3207

1.10B

88.48%

-11.56M

2024Q2

3188

1.10B

88.24%

-14.37M

2024Q1

3196

1.10B

88.13%

-22.04M

2023Q4

3252

1.11B

88.75%

-8.79M

2023Q3

3190

1.10B

88.14%

-23.58M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

118.39M

9.54%

-392.37K

-0.33%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

72.73M

5.86%

+1.93M

+2.72%

Sep 30, 2025

State Street Investment Management (US)

59.09M

4.76%

-98.86K

-0.17%

Sep 30, 2025

Fidelity Management & Research Company LLC

53.80M

4.34%

+39.02K

+0.07%

Sep 30, 2025

Capital World Investors

45.18M

3.64%

-1.12M

-2.43%

Sep 30, 2025

Dodge & Cox

30.13M

2.43%

-685.19K

-2.22%

Sep 30, 2025

Capital Research Global Investors

30.01M

2.42%

-1.08M

-3.48%

Sep 30, 2025

Geode Capital Management, L.L.C.

29.93M

2.41%

+721.32K

+2.47%

Sep 30, 2025

Invesco Capital Management (QQQ Trust)

27.84M

2.24%

+1.83M

+7.02%

Dec 31, 2025

Wellington Management Company, LLP

25.62M

2.06%

-11.91M

-31.74%

Sep 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: sex, 5 de dez

Nome

Proporção

VanEck Biotech ETF

12.54%

ProShares Ultra Nasdaq Biotechnology

8.6%

Invesco Nasdaq Biotechnology ETF

8.54%

iShares Biotechnology ETF

7.24%

Simplify Health Care ETF

7.21%

Invesco Pharmaceuticals ETF

5.11%

Invesco Biotechnology & Genome ETF

5.08%

ProShares Nasdaq-100 Dorsey Wright Momentum ETF

4.62%

First Trust NASDAQ Pharmaceuticals ETF

4.12%

Tema Heart & Health ETF

3.95%

Ver Mais

VanEck Biotech ETF

Proporção12.54%

ProShares Ultra Nasdaq Biotechnology

Proporção8.6%

Invesco Nasdaq Biotechnology ETF

Proporção8.54%

iShares Biotechnology ETF

Proporção7.24%

Simplify Health Care ETF

Proporção7.21%

Invesco Pharmaceuticals ETF

Proporção5.11%

Invesco Biotechnology & Genome ETF

Proporção5.08%

ProShares Nasdaq-100 Dorsey Wright Momentum ETF

Proporção4.62%

First Trust NASDAQ Pharmaceuticals ETF

Proporção4.12%

Tema Heart & Health ETF

Proporção3.95%

Dividendo



Um total de 15.04B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Oct 30, 2025

GILD.NB Final Cash Dividend of gross USD 0.79 paid on Dec 30, 2025 going ex on Dec 15, 2025

Dec 15, 2025

Dec 30, 2025

Dec 15, 2025

Aug 07, 2025

GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Sep 29, 2025 going ex on Sep 15, 2025

Sep 15, 2025

Sep 29, 2025

Sep 15, 2025

Apr 24, 2025

GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Jun 27, 2025 going ex on Jun 13, 2025

Jun 13, 2025

Jun 27, 2025

Jun 13, 2025

Feb 11, 2025

GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Mar 28, 2025 going ex on Mar 14, 2025

Mar 14, 2025

Mar 28, 2025

Mar 14, 2025

Nov 12, 2024

GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024

Dec 13, 2024

Dec 30, 2024

Dec 13, 2024

Aug 13, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024

Sep 13, 2024

Sep 27, 2024

Sep 13, 2024

Apr 26, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024

Jun 14, 2024

Jun 27, 2024

Jun 14, 2024

Feb 06, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024

Mar 15, 2024

Mar 28, 2024

Mar 14, 2024

Nov 08, 2023

GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023

Dec 15, 2023

Dec 28, 2023

Dec 14, 2023

Aug 07, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Sep 28, 2023 going ex on Sep 14, 2023

Sep 15, 2023

Sep 28, 2023

Sep 14, 2023

Ver Mais

Desdobramento de ações



Data

Data ex-dividendo

Tipo

Proporção

Sem dados

Data

Data ex-dividendo

Tipo

Proporção

Sem dados

KeyAI

